PREDAIR FORTE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PREDAIR FORTE (PREDAIR FORTE).
Prednisolone is a glucocorticoid that binds to the glucocorticoid receptor, altering gene expression to produce anti-inflammatory and immunosuppressive effects.
| Metabolism | Primarily hepatic via CYP3A4, also metabolized by 11β-hydroxysteroid dehydrogenase and 20-keto reduction. |
| Excretion | Prednisolone (active metabolite of prednisone) is eliminated primarily via renal excretion of inactive metabolites (approximately 80-90%) and to a minor extent via fecal excretion (approximately 10-20%). Less than 1% of the dose is excreted unchanged in urine. |
| Half-life | The terminal elimination half-life of prednisolone is approximately 2-4 hours in adults. In children, the half-life may be shorter (1-3 hours). The half-life can be prolonged in patients with hepatic impairment or severe renal disease. This short half-life allows for alternate-day dosing to minimize hypothalamic-pituitary-adrenal (HPA) axis suppression. |
| Protein binding | Prednisolone is approximately 70-90% bound to plasma proteins, primarily to corticosteroid-binding globulin (CBG, transcortin) and albumin. Binding is concentration-dependent and saturable at high doses. |
| Volume of Distribution | The apparent volume of distribution (Vd) of prednisolone is 0.5-1.0 L/kg. This suggests distribution into total body water and some tissue binding, but limited by high protein binding. Vd may increase in hypoalbuminemia. |
| Bioavailability | Oral bioavailability of prednisolone is approximately 70-80% after a single dose, with peak plasma concentrations occurring within 1-2 hours. Food may delay absorption but does not significantly reduce total bioavailability. For prednisone (prodrug), bioavailability is similar after conversion to prednisolone. |
| Onset of Action | Oral administration: Onset of anti-inflammatory effects occurs within 2-4 hours. Peak clinical effects may be delayed for several days. Intravenous administration: Onset of action is more rapid, within minutes to hours, depending on the condition. |
| Duration of Action | The duration of anti-inflammatory and immunosuppressive effects lasts 24-36 hours after a single oral dose. Clinical effects may persist for 2-4 days after cessation of chronic therapy due to tissue binding and genomic effects. HPA axis suppression can last for weeks after discontinuation. |
0.5-1.5 mL (5-15 mg prednisolone equivalent) injected subconjunctivally or peribulbarly as a single dose; may repeat weekly if needed. For systemic use, 5-60 mg/day oral prednisolone equivalent, divided 1-2 times daily.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dose adjustment required for renal impairment. GFR-based modifications are not indicated as prednisolone is primarily metabolized hepatically. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 25-50% due to reduced clearance. Child-Pugh C: avoid use or use with extreme caution; dose reduction of 50% or more recommended. |
| Pediatric use | Children: 0.1-2 mg/kg/day orally as prednisolone equivalent, divided 1-4 times daily, tapering to lowest effective dose. For ophthalmic use: 0.1-0.5 mL per eye as a single injection; frequency individualized. |
| Geriatric use | Use lowest effective dose with gradual taper. Monitor for osteoporosis, hyperglycemia, and cardiovascular effects. Consider osteoporosis prophylaxis (calcium, vitamin D) for long-term use. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PREDAIR FORTE (PREDAIR FORTE).
| Breastfeeding | Prednisolone enters breast milk with an estimated M/P ratio of 0.15–0.45. At maternal doses ≤40 mg/day, infant exposure is <10% of maternal dose and considered compatible with breastfeeding. Higher doses may require monitoring infant for adrenal suppression. |
| Teratogenic Risk | Prednisolone acetate (PREDAIR FORTE) crosses the placenta. First trimester: increased risk of orofacial clefts (odds ratio ~3.4). Second/third trimester: associated with fetal adrenal suppression, low birth weight, and preterm delivery. Chronic use may cause intrauterine growth restriction. |
■ FDA Black Box Warning
None
| Serious Effects |
["Systemic fungal infections","Hypersensitivity to prednisolone or any component","Administration of live or live-attenuated vaccines (relative)"]
| Precautions | ["May cause immunosuppression and increased risk of infections.","May cause adrenal suppression with prolonged use.","May cause osteoporosis, cataracts, and glaucoma.","May cause gastrointestinal perforation in patients with certain GI disorders.","May cause growth suppression in children.","May cause Cushing's syndrome with chronic use.","May cause psychiatric disturbances.","May mask signs of infection."] |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal blood pressure, blood glucose (steroid-induced hyperglycemia), and signs of infection. Fetal monitoring: serial ultrasound for growth restriction (every 4–6 weeks) and assessment of amniotic fluid volume. Consider nonstress test or biophysical profile after 32 weeks. |
| Fertility Effects | No direct impairment of fertility documented. However, systemic corticosteroids may disrupt menstrual cycles (anovulation) due to alteration of gonadotropin release; effects are reversible upon dose reduction/discontinuation. |